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Summary 
Chronic coinfection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is associated with adverse 
liver outcomes. The clinical impact of previous HBV infection on liver disease in HCV infection is 
unknown. We aimed to determine any association of previous HBV infection with liver outcomes 
using antibodies to the hepatitis B core antigen (HBcAb) positivity as a marker of exposure. The 
Scottish Hepatitis C Clinical Database containing data for all patients attending HCV clinics in 
participating health boards was linked to the HBV diagnostic registry and mortality data from 
Information Services Division, Scotland. Survival analyses with competing risks were constructed for 
time from the first appointment to decompensated cirrhosis, hepatocellular carcinoma (HCC) and 
liver-related mortality. Records of 8513 chronic HCV patients were included in the analyses (87 
HBcAb positive & HBV surface antigen [HBsAg] positive, 1577 HBcAb positive & HBsAg negative, and 
6849 HBcAb negative). Multivariate cause-specific proportional hazards models showed previous 
HBV infection (HBcAb positive & HBsAg negative) significantly increased the risks of decompensated 
cirrhosis (hazard ratio [HR]: 1.29, 95% CI: 1.01-1.65) and HCC (HR: 1.64, 95% CI: 1.09-2.49), but not 
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liver-related death (HR: 1.02, 95% CI: 0.80-1.30). This is the largest study to date showing an 
association between previous HBV infection and certain adverse liver outcomes in HCV infection. 
Our analyses adds significantly to evidence which suggests HBV infection adversely affects liver 
health despite apparent clearance. This has important implications for HBV vaccination policy and 
indications for prioritisation of HCV therapy. 
 
Keywords 
Cirrhosis, decompensation, hepatitis B core antigen, hepatocellular carcinoma, vaccination, viral 
hepatitis 
 
INTRODUCTION 
Hepatitis C virus (HCV) infection is one of the leading causes of liver morbidity and mortality 
worldwide. It affects 2% of the population, being the leading global indication for liver transplant. 
However, while some patients have a rapidly progressive disease course, less than half of those 
chronically infected will go on to develop liver cirrhosis after 30 years of infection. The influences on 
disease progression are incompletely understood although environmental, viral and genetic 
variables have been shown to accelerate liver fibrosis. With the advent of effective but expensive 
direct acting antiviral (DAA) therapies for HCV, identifying those at the highest risk of liver disease 
progression is necessary to optimise the cost-utility of such therapies, which can vary greatly 
between individual clinical scenarios. One factor consistently associated with poorer outcome is the 
presence of additional liver pathologies.1-3 As detailed in the AASLD/IDSA guidance on HCV 
treatment, these include alcohol excess and active coinfection with other hepatotropic viruses such 
as hepatitis B virus (HBV).3 The majority of adults exposed to HBV will clear the virus from their 
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serum. Despite this, HBV DNA has the potential to remain in hepatocytes as covalent closed circular 
DNA (cccDNA) long after viremia has resolved.4 The effect of previous HBV infection on HCV 
associated liver disease has not yet been determined. 
 
In the event of acute infection with HBV, 95% of healthy adults will appear to clear the 
infection with undetectable hepatitis B surface antigen (HBsAg) and development of hepatitis B 
surface antibodies (HBsAb) and hepatitis B core antigen (HBcAb) with undetectable serum HBV DNA 
using commercial assays. However, in the liver, HBV cccDNA has the potential to persist in 
hepatocytes for many years.4 The replicative potential of this ‘occult’ HBV DNA is well recognized as 
HBV reactivation following immunosuppression is not uncommon. Indeed, for those with evidence 
of previous HBV infection undergoing immunosuppressive therapy, guidelines now recommend 
active monitoring and prophylactic antiviral therapy.5 
The prevalence of DNA persistence in hepatocytes, also termed occult HBV infection (OBI) 
following viral clearance is unknown. For those with serological markers of previous infection such as 
HBcAb and HBV DNA, prevalence varies depending on sensitivity of testing. Several papers have 
highlighted a link between OBI and poor liver outcomes. This has been predominantly reported in 
the context of chronic HCV where detection of HBV DNA in the liver is associated with accelerated 
liver fibrosis, increased risk of hepatocellular carcinoma (HCC) and lower response rates to dual HCV 
therapy.6-9 A study using nested HBV PCR in liver biopsies of HCV positive, HBsAg negative patients to 
detect OBI revealed more severe liver disease in the OBI positive group.10 Recent meta-analyses 
have concluded OBI significantly increases the risk of chronic liver disease and HCC.11 However, most 
of the analyses included in these studies are small and in selected population. In addition, previous 
research has not had sufficient power to correct for possible confounding factors such as alcohol 
abuse and HCV genotype, which have been shown to influence clinical outcomes in chronic HCV 
infection. 
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Determining the impact of PCR proven OBI in a large population of patients with HCV would 
be impractical, particularly as liver biopsy has been largely replaced by non-invasive methods in the 
routine assessment of HCV liver disease. However, it should be possible to explore any effect 
associated with previous HBV infection using HBcAb positivity as a reliable surrogate marker to 
identify individuals who have been exposed to HBV. The Scottish health system provides a unique 
opportunity for epidemiological studies of HCV outcomes. The vast majority of healthcare is 
provided by the state-funded sector with each individual being allocated a unique identifier number, 
enabling their care to be tracked across different geographical locations. We aimed to analyse the 
Scottish Hepatitis C Clinical Database linked to the hepatitis B diagnostic registry data to determine if 
presence of a positive HBcAb status was associated with adverse liver outcomes in patients 
diagnosed with chronic HCV infection. Primary outcomes were development of decompensated 
cirrhosis, HCC, and liver-related mortality. 
 
MATERIALS AND METHODS 
Data sources and linkage 
The Scottish Hepatitis C Clinical Database consists of standalone Microsoft Access databases 
installed across 17 of 18 Scottish HCV treatment centres. These databases hold information on all 
aspects of HCV care and patient management, in addition to information on complications of liver 
disease and other lifestyle factors such as alcohol excess and smoking status.  
All HCV PCR or RNA positive records from the Scottish Hepatitis C Clinical Database were 
electronically linked with HBV serology results extracted from the hepatitis B diagnostic registry data 
(which contains all HBV testing records in Scotland), and to data from Scottish Information Services 
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Division, which provides accurate mortality information and has been used successfully in several 
observational studies of the HCV-infected population.12,13 Individuals were excluded if they had 
never attended a HCV clinic appointment or if the date of clinical outcomes (decompensated 
cirrhosis or HCC) predated the date of their first appointment. 
 
Presence of decompensated cirrhosis was recorded if presence of ascites, jaundice, bleeding 
oesophageal varices or encephalopathy was documented in the Hepatitis C Clinical Database with 
the corresponding dates of laboratory tests. Although data on clinical diagnosis of cirrhosis without 
decompensation were available from the database, frequency of surveillance for cirrhosis varied 
between centres, therefore this was not included as a primary outcome in this study. Diagnosis of 
HCC was by the treating clinician based on radiological findings, the tumour marker alpha-
fetoprotein and, in some circumstances, biopsy according to UK guidelines.14 The diagnosis was 
validated by the reginal hepatobiliary cancer multidisciplinary teams. Date of HCC was recorded as 
the date of the first radiological examination suggesting the diagnosis of HCC. Date and causes of 
death were recorded in data from Information Services Division, Scotland. Liver-related mortality 
was determined through the International Classification of Disease (ICD) codes K70-K77, C22-C24 
and B15-B19. 
 
Study design and statistical analyses 
Individuals included were grouped according to HBV status as either HBV infected (HBcAb positive, 
HBsAg positive), HBV exposed (HBcAb positive, HBsAg negative), HBV unexposed (HBcAb negative) 
and HBV status unknown. Demographic data was collected for all of these categories, however those 
with unknown HBV status were excluded from further univariate and multivariate survival analyses. 
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Age at the first appointment was summarised as median with interquartile range and the other 
categorical variables were summarised as frequencies with percentages. 
 
As the majority of individuals in the Hepatitis C Clinical Database had no known date of HCV 
infection, date of first appointment was chosen as a starting point (baseline) for survival analyses. It 
was necessary to take account of the phenomenon of competing risks for our outcomes of interest, 
since an individual was at risk of more than one mutually exclusive event, and the occurrence of one 
of these would prevent any other event from happening. Specifically, in this study all-cause mortality 
might be a competing risk of decompensated cirrhosis and HCC, while non-liver related death might 
be a competing risk of liver-related death. Therefore cause-specific hazard functions were modelled 
under a proportional hazards assumption to investigate the association between HBcAb positivity 
and decompensated cirrhosis, HCC and liver-related mortality. Time to decompensated cirrhosis and 
HCC was censored at the date of last follow-up (if recorded in the database) or date of death (if the 
last follow-up date was missing). Time to liver-related death was censored at the date of non-liver 
related death (if recorded). 
 
For the univariate analyses, only the covariate ‘HBV status’ was included. For the 
multivariate analyses, other characteristics at baseline (date of the first appointment) recorded in 
the database (age, gender, ethnicity, HCV genotype, ever injection drug use [IDU], ever smoking, 
alcohol excess defined as a history of regular consumption of greater than 50 units per week, and 
HIV coinfection) were also included. Assuming that data was missing at random, multiple imputation 
procedures were conducted to impute missing baseline data on alcohol excess, HIV coinfection, ever 
smoking, HCV genotype, ever IDU and ethnicity. The imputation model included all variables related 
to the outcomes as well as the censoring indicator and the observed time to event, with binary 
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logistic regression for two-level factors and polytomous logistic regression for factors have more 
than 2 levels. For each of the three outcomes of interest, cause-specific proportional hazards model 
was fitted to 5 imputed datasets. The estimates of hazard ratios and p values from each imputed 
dataset were combined to produce inferential results. Proportional hazard assumptions were also 
tested by creating interactions with logarithm of time for all the covariates included in the models. 
 
RESULTS 
Study cohort 
There were 21787 patients in the Scottish hepatitis B diagnostic registry data and 18603 patients in 
the Scottish Hepatitis C Clinical Database. After data linkage and exclusion of the patients who had 
developed primary outcomes prior to their first appointment, a total of 12209 patients were 
included in this study. The description of all the individuals included according to their HBV status is 
shown in Table 1. Of the 8513 patients with known HBV status, 87 (1%) were overtly HBV co-infected 
(HBcAb positive & HBsAg positive), 1577 (18.5%) had evidence of HBV exposure (HBcAb positive & 
HBsAg negative), and 6849 (80.5%) had no evidence of previous HBV exposure. The 3696 patients 
with HCV infection but unknown HBV status were only described for baseline demographics and 
were excluded in further analyses. 
The HBV exposed group tended to be older at the first clinic appointment, with higher rates 
of reported alcohol excess, smoking, IDU and HIV coinfection than the unexposed group. For the 
8513 patients with unknown HBV status, the median duration of follow-up from date of the first 
appointment to events or censoring was 3.3 years with the interquartile range 1.4 to 7.4 years. The 
variables with missing values were alcohol excess (32.9%), HIV coinfection (29.7%), ever smoking 
(25.9%), HCV genotype (12.4%), ever IDU (7.1%) and ethnicity (0.8%). 
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Univariate and multivariate analyses 
Univariate analyses (Table 2) revealed significantly higher risk of decompensated cirrhosis (HR: 1.50, 
95% CI: 1.18 – 1.90) and HCC (HR: 1.57, 95% CI: 1.06 – 2.34) in the HBV exposed group (HBcAb 
positive & HBsAg negative) compared to those with known HBcAb negative status. However, 
exposure to HBV did not significantly increase the risk of liver-related mortality (HR: 1.23, 95% CI: 
0.98 – 1.56). 
 
Multivariate analyses (Table 3) showed that exposure to HBV (HBcAb positive & HBsAg 
negative) significantly increased the risk of decompensated cirrhosis (HR: 1.29, 95% CI: 1.01 – 1.65) 
and HCC (HR: 1.64, 95% CI: 1.09 – 2.49), while it did not significantly increase the risk of liver-related 
mortality (HR: 1.02, 95% CI: 0.80 – 1.30). We did not observed a statistically significant association 
between overt HBV infection (HBcAb positive & HBsAg positive) and the outcomes measured. The 
proportions of patients in this group developing decompensated cirrhosis (6.9%) and HCC (2.3%) 
suggested a trend to poorer liver outcomes compared to those unexposed to HBV (3.5% and 1.2% 
respectively). In the multivariate analysis of decompensated cirrhosis, there was a lower risk if ever 
IDU (HR: 0.56, 95% CI: 0.43 – 0.72) perhaps because people who injected drugs (PWID) might be 
diagnosed HCV infection earlier than those who did not due to screening. Since date at the first 
appointment was used as the starting time point, PWID would tend to be younger at the start of 
follow up and had a longer time to events interested. Violation of proportional hazard assumptions 
were not found in any of the multivariate models.  
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DISCUSSION 
Our data suggested a strong link between serological evidence of previous HBV infection and 
development of decompensated cirrhosis and HCC in patients with HCV. This association remains 
significant event once confounders such as history of alcohol excess, IDU, age at the first clinic 
appointment and smoking history have been taken into account. This is the largest study to confirm 
that previous HBV infection is an important factor in HCV liver disease outcomes, which may also 
have implications for other liver conditions. 
 
Within Scotland, the majority of individuals who do become infected with HCV take part in 
risk prone behaviours such as IDU or are immigrants from highly endemic areas. Such individuals are 
also at risk of HBV exposure. Within HCV infected populations 2-10% have overt HBV infection.15 In 
overt chronic coinfection with HBV and HCV viruses, one virus often replicates at lower levels which 
may lead to difficulties in diagnosis.16 Despite apparent viral suppression, co-infected individuals 
have been reported to have higher rates of liver fibrosis and HCC. 
 
HBV is effectively prevented using a recombinant HBsAg-based vaccine, while many 
countries have now adopted universal HBV vaccination policies, within the UK vaccination is limited 
to individuals in high risk groups.17 Despite being eligible for vaccination, up to 23% of the British 
PWID population have detectable antibodies to the HBcAb.18 This suggests many were exposed to 
HBV prior to taking up vaccination, although some may have been infected before the vaccine was 
introduced. The challenges of identifying and vaccinating PWID during their most high-risk periods of 
use are well recognized, and worldwide HBcAb positivity is reported between 2-85% of PWID.19 
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The association of HBcAb positivity with more rapid progressive liver disease has several 
possible explanations: (i) persistence of HBV DNA in a significant proportion of those with prior 
infection of HBV occurs and increases the risk of decompensated cirrhosis and HCC; (ii) acute HBV 
infection and the inflammation associated with its clearance predisposes to a greater risk of cirrhosis 
with subsequent chronic HCV infection; (iii) failure of HBV vaccination and subsequent infection 
occurs in those with more severe liver disease; and (iv) previous HBV infection is simply a marker of 
certain individual traits, e.g. more chaotic / longer drug injecting history or poor compliance with 
medical intervention such as HBV vaccination which in turn could be associated with worse 
outcomes. 
 
Persistent HBV DNA 
Occult hepatitis B infection would present one of the most biologically plausible explanations for the 
excess liver morbidity in the HBV exposed group. If HBV DNA persistence and low levels of DNA 
replication are present in a significant proportion of those individuals previously infected, this could 
potentiate some of the molecular mechanisms of cellular damage induce by HCV in a similar way to 
overt coinfection. Of note, the European Medicines Agency has recently initiated an investigation of 
HBV reactivation following DAA therapy for HCV. This follows publication of case reports describing 
reactivation of HBV following successful DAA therapy for HCV, in two cases the only marker of HBV 
infection was HBcAb positivity.20,21 Suppression of one virus by another is well documented and 
these cases provide further evidence that in the context of chronic HCV infection, ‘cleared’ HBV may 
in fact be suppressed HBV with the potential to cause ongoing liver damage.22 
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The means by which coinfection induces higher levels of cellular damage are incompletely 
understood. However, there is evidence that HBV and HCV have shared mechanisms for inducing 
cellular stress which could become synergistic in the presence of both viruses to enhance 
fibrogenesis.23 In addition, upregulation of proto-oncogenes are seen in both HBV and HCV which 
may predispose to liver damage and eventually HCC.24 While we did not demonstrate a significant 
association between HBsAg positivity and adverse outcomes, these associations have been reported 
elsewhere and we did find a trend toward adverse outcomes and it is likely we were unable to 
detect an association due to the relatively small number of patients and events in this group in our 
cohort.1,15 
Our study hinges on using HBcAb as a surrogate for OBI. In the setting of chronic HBV 
infection, HBcAb has a specificity of above 95% and an overall accuracy of 90% as a surrogate marker 
for ever infection,25 we can assume that of those testing positive for HBcAb, at least 95% will have 
been exposed to HBV. Association of outcomes with previous infection may be weakened by 
individuals who lose HBcAb over time, however this does not introduce risk of a Type I error in our 
study. The use of HBcAb to determine OBI is less clear cut. It has been found that HBcAb has a 
sensitivity of 54% and specificity of 72% for OBI in a HCV positive population, with a positive 
predictive value of 56%.10 Similarly, another study found 62% of those with HBcAb had evidence of 
viral DNA in their liver.26 It must be remembered that extracting cccDNA from liver tissue that has 
been stored in various conditions for retrospective analysis is not a ‘gold standard’ and thus more 
patients with HBcAb may have OBI. Even if we accept that not all patients with HBcAb have OBI, it 
does not exclude our observation of worsened outcome in those with HCV and HBcAb being 
attributable to OBI. It is possible that exposure to HBV infection could cause lasting liver damage by 
mechanisms other than DNA persistence. Indeed, some studies have raised the possibility that 
previous HBV infection alone may be linked to poorer liver disease outcomes without the presence 
of OBI.27,28  
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Vaccination uptake and efficacy 
There were insufficient clinical data to determine if any of those with positive HBcAb status had 
taken up vaccination which was subsequently unsuccessful, with or without the influence of 
advanced liver disease. However, rates of vaccine efficacy are almost 90% in those with 
compensated cirrhosis and higher in those without significant liver disease.29 Given the low rates of 
vaccine uptake in PWID population it is improbable that the association with HBcAb and cirrhosis is 
due to vaccine non-response and then subsequent infection with HBV is already in cirrhotic 
individuals. 
 
While it is possible that those exposed to HBV have riskier behaviours, a study of Australian 
PWID shows that individuals who are unvaccinated against HBV are more likely to be male and do 
not have more high-risk patterns of drug use.30 To explore this hypothesis in the Scottish population, 
we also analysed the relationship between HBV status and all-cause mortality. This analysis showed 
a strong association between IDU and mortality but no significant increase in all-cause mortality risk 
with HBcAb positivity (Table 4). 
 
A sub-analysis of the HBcAb negative cohort was also preformed to determine any 
differences between those with evidence of vaccination (HBsAb positive) and those without (Table 
5). In this cohort, vaccinated individuals were more likely to be younger, male, Caucasian, having a 
history of IDU, and be smokers compared to unvaccinated individuals (p < 0.001 for these 
characteristics). In addition to the 18.5% of the HCV population known to be exposed to HBV, 62% of 
the Scottish HCV population had not been vaccinated at the point of presenting with HCV which 
suggests that historically the UK vaccination policy was failing to adequately protect individuals at 
risk of HBV. 
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Implications for HCV therapy 
Although recent guidance of National Institute for Health and Care Excellence has suggested 
direct acting antivirals can be used for all HCV infected patients with genotype 1 infection, 
the cost of provision for all HCV infected individuals will be considerable. Ideally, healthcare 
providers should prioritise treatment for patients where this will result in the biggest 
improvement in health outcomes. Early access programmes in the UK have largely been 
targeted at those with more advanced disease. Identifying individuals whose liver disease 
may progress more rapidly, e.g. those with previous HBV exposure, may help target those 
who will benefit most from treatment in earlier stages of the disease. 
 
Limitations of analysis 
One common limitation encountered in observational research in HCV infected populations is 
uncertainty around time of infection. In this study, the majority of individuals do not have a known 
date of infection with HCV or exposure to HBV. Various studies have reported ways of accounting for 
this, either by assuming infection at a certain age or at a specific point following date of reported 
commencement of IDU. In this study we have used date of first clinic appointment as a surrogate 
while including age at first clinic appointment as a covariate in the multivariate analysis and 
excluding those developing primary outcomes prior to first appointment. This approach introduces 
risk of a Type II error by automatically excluding any individual with decompensated cirrhosis or HCC 
at diagnosis but should not falsely inflate the rate of adverse liver outcomes in one particular group. 
In addition, as HCV clearance does not always prevent future progression to decompensated 
cirrhosis or HCC, particularly in the presence of other liver pathologies, we chose not to include it in 
this study. 
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Conclusions 
This is the largest study to date to show an association between previous HBV infection and adverse 
liver outcomes (decompensated cirrhosis and HCC) in a large, unselected population of individuals 
with chronic HCV. Our results confirm a growing body of evidence which suggests HBV infection may 
have adverse effects on liver health despite apparent viral clearance. Our data also suggest that UK 
vaccination policies failed to prevent HBV infection in a substantial number of individuals at risk 
although novel approaches targeting high risk groups may be more effective. The current HCV 
therapy guideline focussed on prioritizing patients with advanced disease should be reconsidered to 
include HBV coinfection and prior exposure. Our findings have important implications for the UK 
HBV vaccination policy and global HCV therapy policies. 
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Tables 
Table 1. Description of study population (total number = 12209), according to HBV status. 
Demographics  
& outcomes 
Subgroups according to HBV status 
Co-infected 
(n = 87) 
Exposed 
(n = 1577) 
Unexposed 
(n = 6849) 
Unknown 
(n = 3696) 
Age at 1
st
 clinic appointment 34 (30 - 42) 39 (33 - 45) 35 (29 - 42) 37 (30 - 44) 
Male gender  69 (79%) 1202(76%) 4836 (71%) 2524 (68%) 
Ethnicity White 81 (93%) 1455 (92%) 6454 (94%) 3517 (95%) 
 Non-white 6 (7%) 108 (7%) 345 (5%) 140 (4%) 
 Unknown 0 (0%) 14 (1%) 50 (1%) 39 (1%) 
HCV genotype 1 32 (37%) 619 (39%) 2716 (40%) 1192 (32%) 
 3 30 (34%) 696 (44%) 2864 (42%) 1311 (35%) 
 Others 3 (3%) 89 (6%) 411 (6%) 175 (5%) 
 Unknown 22 (25%) 173 (11%) 858 (13%) 1018 (28%) 
Ever IDU Yes 54 (62%) 1218 (77%) 4810 (70%) 2260 (61%) 
 No 19 (22%) 258 (16%) 1551 (23%) 766 (21%) 
 Unknown 14 (16%) 101 (6%) 488 (7%) 670 (18%) 
Ever smoking Yes 44 (51%) 1075 (68%) 4383 (64%) 1894 (51%) 
 No 9 (10%) 140 (9%) 611 (9%) 284 (8%) 
 Unknown 34 (39%) 362 (23%) 1805 (26%) 1518 (41%) 
Alcohol intake >50 u/w 20 (23%) 424 (27%) 1599 (23%) 735 (20%) 
 ≤50 u/w 32 (37%) 696 (44%) 2938 (43%) 1435 (39%) 
 Unknown 35 (40%) 457 (29%) 2312 (34%) 1526 (41%) 
HIV coinfection Yes 8 (9%) 72 (5%) 75 (1%) 75 (2%) 
 No 47 (54%) 1073 (68%) 4713 (69%) 1355 (37%) 
 Unknown 32 (37%) 432 (27%) 2061 (30%) 2266 (61%) 
Decompensated cirrhosis 6 (6.9%) 95 (6.0%) 239 (3.5%)  
HCC  2 (2.3%) 35 (2.2%) 80 (1.2%)  
Liver-related death  4 (4.6%) 96 (6.1%) 260 (3.8%)  
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Table 2. Hazard ratios (95% CI) and p values from univariate cause-specific hazard models for 
decompensated cirrhosis, HCC and liver-related mortality. 
 HR (95% CI) p 
Decompensated cirrhosis   
HBcAb[+] & HBsAg[+] vs HBcAb[-] 1.88 (0.83 – 4.22) 0.128 
HBcAb[+] & HBsAg[-] vs HBcAb[-] 1.50 (1.18 – 1.90) 0.001 
HCC   
HBcAb[+] & HBsAg[+] vs HBcAb[-] 1.78 (0.44 – 7.23) 0.423 
HBcAb[+] & HBsAg[-] vs HBcAb[-] 1.57 (1.06 – 2.34) 0.025 
Liver-related mortality   
HBcAb[+] & HBsAg[+] vs HBcAb[-] 1.06 (0.40 – 2.85) 0.904 
HBcAb[+] & HBsAg[-] vs HBcAb[-] 1.23 (0.98 – 1.56) 0.080 
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Table 3. Hazard ratios (95% CI) and p values from multivariate cause-specific hazard models for 
decompensated cirrhosis, HCC and liver-related mortality. 
Covariates 
Decompensated cirrhosis HCC Liver-related mortality 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Age at 1st clinic appointment 1.07 (1.06 – 1.08) <0.001 1.12 (1.10 – 1.14) <0.001 1.10 (1.09 – 1.11) <0.001 
Gender       
Male vs Female 1.16 (0.90 – 1.49) 0.264 2.90 (1.70 – 4.93) <0.001 1.31 (1.01 – 1.71) 0.041 
Ethnicity       
White vs Non-white 0.88 (0.54 – 1.45) 0.632 1.87 (0.80 – 4.40) 0.152 1.60 (0.87 – 2.96) 0.140 
HCV genotype       
Genotype 3 vs Genotype 1 1.10 (0.88 – 1.38) 0.431 1.42 (0.96 – 2.09) 0.101 1.40 (1.12 – 1.74) 0.003 
Other types vs Genotype 1 0.62 (0.39 – 1.00) 0.053 0.37 (0.15 – 0.94) 0.037 0.64 (0.41 – 1.01) 0.065 
Ever IDU 0.56 (0.43 – 0.72) <0.001 0.65 (0.41 – 1.04) 0.077 1.12 (0.85 – 1.47) 0.437 
Ever smoking 1.14 (0.80 – 1.63) 0.521 0.88 (0.53 – 1.47) 0.594 1.08 (0.77 – 1.53) 0.530 
Alcohol excess (>50units/week) 3.31 (2.61 – 4.20) <0.001 1.78 (1.20 – 2.65) 0.006 2.78 (2.21 – 3.50) <0.001 
HIV coinfection 2.23 (1.39 – 3.57) 0.002 0.32 (0.05 – 2.31) 0.259 1.75 (1.02 – 2.98) 0.105 
HBV status       
HBcAb[+] & HBsAg[+] vs HBcAb[-] 1.80 (0.79 – 4.07) 0.190 2.57 (0.62 – 10.52) 0.194 1.32 (0.49 – 3.57) 0.602 
HBcAb[+] & HBsAg[-] vs HBcAb[-] 1.29 (1.01 – 1.65) 0.043 1.64 (1.09 – 2.49) 0.019 1.02 (0.80 – 1.30) 0.821 
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Table 4. Hazard ratios (95% CI) and p values from multivariate cause-specific hazard models for all-cause 
mortality. 
Covariates HR (95% CI) p 
Age at 1
st
 clinic appointment 1.07 (1.06 – 1.08) < 0.001 
Gender    
Male vs Female 1.21 (1.03 – 1.42) 0.018 
Ethnicity   
White vs Non-white 1.47 (0.94 – 2.31) 0.103 
HCV genotype   
Genotype 3 vs Genotype 1 1.41 (1.23 – 1.61) < 0.001 
Other types vs Genotype 1 1.10 (0.85 – 1.42) 0.520 
Ever IDU 1.79 (1.49 – 2.16) < 0.001 
Ever smoking 1.21 (0.95 – 1.53) 0.214 
Alcohol excess (> 50 units/week) 1.96 (1.71 – 2.25) < 0.001 
HIV coinfection 1.56 (1.13 – 2.15) 0.017 
HBV status   
HBcAb[+] & HBsAg[+] vs HBcAb[-] 1.48 (0.88 – 2.49) 0.114 
HBcAb[+] & HBsAg[-] vs HBcAb[-] 0.88 (0.76 – 1.03) 0.146 
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Table 5. Demographics summary of HCV patients with HBcAb negative and known HBsAb status. 
Demographics 
HBcAb(-) & HBsAb(+) 
(n = 2034) 
HBcAb(-) & HBsAb(-) 
(n = 4511) 
p
 
Age at 1
st
 clinic appointment 32 (27 - 38) 36 (29 - 43) < 0.001 
Male gender  1512 (74%) 3103 (69%) < 0.001 
Ethnicity White 1974 (97%) 4195 (93%)  
 Non-white 49 (2%) 284 (6%) < 0.001 
 Unknown 11 (1%) 32 (1%)  
HCV genotype 1 811 (40%) 1769 (39%)  
 3 893 (44%) 1871 (41%) 0.354 
 Others 112 (5%) 277 (6%)  
 Unknown 218 (11%) 594 (13%)  
Ever IDU Yes 1600 (79%) 3012 (67%)  
 No 319 (16%) 1174 (26%) < 0.001 
 Unknown 115 (6%) 325 (7%)  
Ever smoking Yes 1394 (69%) 2809 (62%)  
 No 146 (7%) 497 (11%) < 0.001 
 Unknown 494 (24%) 1205 (27%)  
Alcohol intake >50 u/w 464 (23%) 1063 (24%)  
 ≤50 u/w 811 (40%) 1995 (44%) 0.322 
 Unknown 759 (37%) 1453 (32%)  
HIV coinfection Yes 28 (1%) 42 (1%)  
 No 1447 (71%) 3106 (69%) 0.182 
 Unknown 559 (27%) 1363 (30%)  
P value was obtained from Mann-Whitney test for age at 1st clinic appointment, and from Chi-squared test for the others. 
 
 
